John W. Semple

John W. Semple is a Canadian Scientist at St. Michael's Hospital and a Professor of Pharmacology at the University of Toronto. He was born in Windsor, Ontario in 1959 and received his PhD in Immunology at Queen's University at Kingston, Ontario. In 1991, Semple, along with John Freedman, discovered a T helper cell defect in patients with the bleeding disorder called immune thrombocytopenic purpura (ITP).[1] ITP is the condition of having a low platelet count (thrombocytopenia) and most causes appear to be related to antibodies against platelets. Very low platelet counts can lead to a bleeding diathesis and purpura. The T cell defect was initially shown to be an exaggerated interleukin-2 response when T cells were cultured with platelets in vitro. Subsequently, this cytokine abnormality was shown by others to be responsible for many of the autoimmune mechanisms causing the disorder.).[2] [3] [4] [5] [6] The importance of understanding the T cell defects in ITP is that novel therapies aimed at these cells may significantly benefit patients with ITP.

References

  1. ↑ JW. Semple; et al. (1991). "Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia". Blood. 78 (10): 2619–25. PMID 1840468.
  2. ↑ N Cooper; et al. (2006). "The pathogenesis of immune thrombocytopaenic purpura". British Journal of Haematology. 133 (4): 364–374. doi:10.1111/j.1365-2141.2006.06024.x. PMID 16643442.
  3. ↑ JW Semple; et al. (1996). "Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity". Blood Journal. 87 (10): 4245–4254. PMID 8639783.
  4. ↑ M Kuwana; et al. (1998). "Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody". J Clin Invest. 87 (7): 1393–1402. doi:10.1172/JCI4238. PMC 508987Freely accessible. PMID 9769332.
  5. ↑ B Olsson; et al. (2003). "T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura". Nature Medicine. 9 (9): 1123–1124. doi:10.1038/nm921. PMID 12937414.
  6. ↑ Stasi R, et al. (2008). "Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab". Blood. 112 (4): 1147–1150. doi:10.1182/blood-2007-12-129262. PMID 18375792.

External links


This article is issued from Wikipedia - version of the 9/3/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.